← Azimuth Daily
Capturing data…
Capturing data…
TUE, 27 OCT · 97 ITEMS
"Neoadjuvant durvalumab plus chemotherapy shows promise in resectable NSCLC" — Nature Medicine · Science & Medicine
This is a phase 2 clinical trial result in which patients with early-stage non-small-cell lung cancer that can be surgically removed ( ) received the immunotherapy drug together with chemotherapy before surgery ( treatment). The finding that this combination 'shows promise' means the trial reported encouraging efficacy or safety signals, though the headline doesn't specify the exact endpoints (e.g., major pathological response, event-free survival) or effect sizes.
The claim sits close to the primary source: a Nature Medicine paper (DOI 10.1038/s41591-026-04742-7) reporting the trial results. As a primary-source publication, the paper is authoritative about its own findings, but the headline's word 'promise' is a summary rather than a precise statistical claim, and the specific effect sizes are not stated here.
Genuinely new: the paper was published on 2026-10-26, and no recirculation year is given, so this is current reporting of the trial's initial results.